Pharma Hemp ®
LABORATORIES

ilac-MRA

SLOVENSKA AKREDITACIJA
SIST EN ISO/IEC 17025
LP-117

CERTIFICATE OF ANALYSIS No.: 2021-5415

CLIENT

CIITECH Ltd, 2 Athenaeum Road
GB-N20 9AE London, United Kingdom

SAMPLE

Provacan CBD e-liquid 300mg / 10ml

Sample condition:	SUITABLE	Work order:	2021-105407	Sample received:	30/07/2021
Sample ID:	2130049	Analysis ID:	2021_174	Start of analysis:	30/07/2021
Sample type:	Viscous liquid	Method ID:	PHL_RPC_12C	End of analysis:	02/08/2021
Batch No.:	EL03021190A	Method SOP:	MET-002	Analyst:	Aleksander Jefim

CANNABINOID PROFILE	Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV - Cannabidivarin	0.431	0.078	
CBDA - Cannabidiolic acid	0.0379	0.0087	
CBGA - Cannabigerolic acid	< LOQ	n/a	
CBG - Cannabigerol	0.050	0.015	
CBD - Cannabidiol	2.88	0.14	
THCV - Tetrahydrocannabivarin	0.088	0.018	
CBN - Cannabinol	< LOQ	n/a	
CBC - Cannabichromene	< LOQ	n/a	
THC - Δ-9-Tetrahydrocannabinol	< LOQ	n/a	
THCA - Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	
8-THC - Δ-8-Tetrahydrocannabinol *	< LOQ	n/a	
CBL - Cannabicyclol *	< LOQ	n/a	

The results marked by * relate to non-accredited activity.

Units and abbreviations: **% w/w** = weight percent, **< LOQ** = below the limit of quantitation (0.03 % w/w), **ND** = not detected, **n/a** = not available.

The results given herein apply only to the sample as received. **Expanded Uncertainty** was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

02/08/2021

Approved by:

mag. Marko Dragan
Analytical Laboratory Manager

Authorized by:

dr. Boštjan Jančar
Chief Technology Officer

End of Certificate